Education
About Us
Working with TipRanks
Follow Us
Gland Pharma Ltd. (IN:GLAND)
:GLAND
RESEARCH TOOLSreports
Total Valuation
Gland Pharma Ltd. has a market cap or net worth of ₹238.93B. The enterprise value is ₹270.82B.
Market Cap₹238.93B
Enterprise Value₹270.82B
Share Statistics
Gland Pharma Ltd. has 164,756,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding164,756,420
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Gland Pharma Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Gland Pharma Ltd. is ―. Gland Pharma Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Gland Pharma Ltd. had revenue of 56.42B and earned 7.72B in profits. Earnings per share was 46.90.
Revenue56.42B
Gross Profit30.88B
Operating Income16.45B
Pretax Income11.33B
Net Income7.72B
EBITDA15.03B
Earnings Per Share (EPS)46.90
Cash Flow
In the last 12 months, operating cash flow was 3.73B and capital expenditures 0.00, giving a free cash flow of 3.73B billion.
Operating Cash Flow3.73B
Free Cash Flow3.73B
Free Cash Flow per Share22.66
Dividends & Yields
Gland Pharma Ltd. pays an annual dividend of ₹20, resulting in a dividend yield of 1.36%
Dividend Per Share₹20
Dividend Yield1.36%
Payout Ratio46.83%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change-14.95%
50-Day Moving Average1.53K
200-Day Moving Average1.74K
Relative Strength Index (RSI)46.43
Average Volume (3m)12.01K
Important Dates
Gland Pharma Ltd. upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateFeb 3, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend DateAug 16, 2024
Financial Position
Gland Pharma Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Gland Pharma Ltd. has paid 3.60B in taxes.
Income Tax3.60B
Effective Tax Rate―
Enterprise Valuation
Gland Pharma Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Gland Pharma Ltd. has ₹18.39B in cash and marketable securities with ₹60.11M in debt, giving a net cash position of -₹18.39B billion.
Cash & Marketable Securities₹18.39B
Total Debt₹60.11M
Net Cash-₹18.39B
Net Cash Per Share-₹111.65
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Gland Pharma Ltd. is ₹1,627.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹1,627.50
Price Target Upside-0.76% Downside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―